June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.
September 2022 in “Scientific Reports” This study found that scalp melanoma often occurs in areas with androgenetic alopecia, and patients without alopecia might experience a later diagnosis due to hair coverage, leading to potentially worse outcomes.
82 citations
,
March 2013 in “PLoS ONE” In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.
7 citations
,
May 2020 in “Trends in molecular medicine” This study explored the immune environment of the hair follicle's bulge region and suggested that its unique signaling may prevent melanoma formation by lacking necessary proinflammatory signals for full oncogenic transformation, indicating potential strategies for melanoma prevention by replicating this immune-privileged environment.
3 citations
,
May 2018 in “The American Journal of Medicine” This case report describes a 33-year-old woman with long-standing scalp issues and hair loss, revealing an unusual connection to past melanoma, but it presents no new research results.